SEHK:9966Biotechs
Assessing Alphamab Oncology’s Valuation After KN026 Phase III Trial Publication
Why the KN026 trial publication matters for Alphamab Oncology
The publication of Alphamab Oncology (SEHK:9966)'s Phase III anbenitamab, or KN026, gastric cancer trial in the Annals of Oncology, highlighting progression free and overall survival benefits versus standard care, gives investors fresh information on a key pipeline asset.
Because this study targets HER2 positive gastric or gastroesophageal junction cancer in patients who have already received trastuzumab containing therapy, it...